Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

Overview of attention for article published in Pediatric Rheumatology, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet

facebook: 1 Facebook page

Citations

dimensions_citation: 87 Dimensions

Readers on

mendeley: 75 Mendeley

Summary News Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Ophthalmology pearls, 31 May 2013

Adalimumab more effective than Infliximab as first-line anti-TNF therapy for childhood uveitis: Adalimumab had better efficacy…